Missionomics Back to app

Healthcare

Zimmer Biomet Holdings, Inc. (ZBH)

Healthcare $17.6B market cap

Data as of July 13, 2026

Environment
60.00
People
72.00
Leadership
78.00

Environment story

Zimmer Biomet has not disclosed Scope 1, 2, or 3 emissions targets, net-zero commitment year, or current emissions data in available filings. The company faces material environmental risks from supply chain disruptions, natural disaster exposure, and manufacturing operations, but no specific environmental controversies or climate commitments are documented. Without disclosed emissions baselines or reduction targets, environmental performance cannot be independently verified. The absence of net-zero or 2050-aligned climate commitments, combined with undisclosed Scope 3 supply-chain emissions (particularly from medical device manufacturing and distribution), results in a materially reduced environmental score.

Criticisms on file

  • Natural disaster and climate change operational risks identified in 10-K as material risk to manufacturing, supply chain, and raw material sourcing; no mitigation strategy disclosed.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'Natural disasters, or legal, regulatory or market measures to address natural disasters, could materially adversely affect our business and financial results.'
  • No disclosure of Scope 3 emissions or supply-chain carbon management despite reliance on global manufacturing and distribution network.
    Source: ZBH_10k.txt — Risk Factors and MD&A sections; no sustainability report or ESG-specific disclosure provided in source materials.

Disclosed initiatives

  • Manufacturing Process Optimization
    Company reports use of Lean and Six Sigma methodologies, computer-assisted robots, multi-axis grinders, and state-of-the-art equipment to improve manufacturing quality and efficiency. Continuous improvement efforts focused on lead-time reduction and capacity optimization.
    Potential indirect reduction in per-unit manufacturing emissions through process efficiency, but no quantified environmental benefit disclosed.
  • Supply Chain Risk Management
    Company evaluates supply chain continuity and works closely with suppliers on quality and reliability; however, no specific environmental or carbon-reduction criteria disclosed for supplier selection.
    Limited environmental impact; focus is on operational resilience rather than decarbonization.

Social story

Zimmer Biomet reports approximately 17,000 employees globally with 7,000 in the U.S. and 10,000 internationally. The company emphasizes employee engagement, wellness programs, and safety initiatives, with reported 2025 Total Recordable Incident Rate of 0.22 and Lost Time Incident Rate of 0.10. However, critical metrics including CEO-to-median-worker pay ratio, workforce diversity percentages, and union standing are undisclosed. The company is undergoing significant organizational transformation (U.S. sales-force conversion from independent distributors to employees; ERP implementation disruptions in 2024; restructuring programs across 2019–2025), which presents turnover and labor management risks. No documented labor disputes or union-suppression activities are reported, but employee engagement survey results and detailed diversity metrics are not disclosed. Supply-chain ethics regarding conflict minerals or human-rights audits are not addressed in available documents.

Criticisms on file

  • Major organizational disruption from 2024 ERP system implementation in Americas caused operational disruptions, distribution delays, order fulfillment challenges, and loss of customers and sales; company acknowledges risk of future ERP implementation disruptions.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'Challenges integrating, transitioning and implementing a new enterprise resource planning (ERP) system have adversely affected our business and operations, and may in the future have further adverse effects.'
  • Multi-year U.S. sales-force transformation from independent distributors to employees presents significant operational, legal, financial, and cultural risks; company acknowledges risk of loss of key sales personnel to competitors and disruption to customer relationships.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'We are transforming aspects of our sales and distribution network and go-to-market model in the U.S. and certain other markets, and these efforts may not be successful and they involve risks and challenges that may adversely impact our business, results of operations and financial condition.'
  • Independent agents and distributors classified as independent contractors; company acknowledges litigation and tax authority challenges to classification, with potential for reclassification as employees and resulting payroll tax and benefit obligations.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'If our independent agents and distributors are characterized as employees, we would be subject to additional tax and other liabilities.'
  • No disclosure of CEO-to-median-worker pay ratio, workforce diversity metrics (women %, underrepresented groups %), or supply-chain human-rights audit findings.
    Source: ZBH_10k.txt and ZBH_proxy.txt — no specific DEI metrics or supply-chain ethics statements provided.

Disclosed initiatives

  • Employee Resource Groups (ERGs)
    Company maintains eight global ERGs with approximately 15% of workforce participation. ERGs receive funding from Zimmer Biomet Foundation to support community partnerships aligned to the company mission.
    Supports employee inclusion and community engagement, but no quantified diversity or retention outcomes disclosed.
  • Employee Engagement and Communication
    Company conducts comprehensive employee engagement surveys assessing five drivers: purpose, culture, leadership, personal growth, and belonging. Results shared with Board and employees; action plans developed based on survey outcomes.
    Demonstrates commitment to transparency and employee voice, though survey results and benchmark scores not disclosed.
  • Health, Safety and Wellness Programs
    Company sponsors wellness programs for physical, mental, and financial wellbeing. Environmental, Health & Safety team monitors metrics continuously. 2025 Total Recordable Incident Rate: 0.22; Lost Time Incident Rate: 0.10; metrics shared with relevant regulatory agencies and Board.
    Low incident rates relative to manufacturing industry standards; demonstrates proactive workplace safety management.
  • Succession Planning and Talent Development
    Board identifies succession planning for senior management and key employees as critical to long-term success. Company acknowledges competition for talent and investment in competitive compensation, benefits, and work arrangement flexibility (remote/hybrid options).
    Addresses human-capital risk, though specific retention and development metrics not disclosed.

Governance story

Zimmer Biomet demonstrates strong governance infrastructure: 100% board independence (9 of 10 directors independent, with CEO as sole non-independent member); annual director election; lead independent director role (Michael J. Farrell since May 2025); 100% independent board committees; proxy access; no dual-class share structure; no supermajority voting; no poison pill; robust clawback policies; mandatory stock ownership and retention guidelines; prohibition on hedging and pledging; and rigorous board evaluation and succession planning processes. However, governance score is reduced due to: (1) substantial debt of $7.5 billion and $7.1 billion goodwill/intangible assets creating financial leverage risk; (2) multiple significant regulatory and legal risks disclosed in 10-K (product liability, IP litigation, healthcare fraud/abuse, data privacy, cybersecurity); (3) active litigation and product liability exposure; (4) lobbying expenditures not specifically quantified but corporate affairs function included in executive compensation structure. No evidence of active lobbying against climate or consumer-protection regulations. The 2024 ERP implementation failure and resulting operational disruptions suggest governance oversight gaps in technology risk management. Board composition includes 9 independent directors with diverse skills and substantial public-company experience.

Criticisms on file

  • Substantial indebtedness of $7.5 billion (up from acquisition activity) creates financial leverage risk and constrains strategic flexibility. Debt service principal obligations of $0.6 billion due within 12 months. Company acknowledges risk that increased debt could limit ability to fund R&D, working capital, and capital expenditures, and could adversely affect credit rating.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'We incurred substantial additional indebtedness in connection with previous mergers and acquisitions, may incur additional substantial indebtedness in connection with future mergers and acquisitions, and may not be able to meet all of our current and future debt obligations.'
  • Material goodwill and intangible assets totaling $9.9 billion in goodwill and $4.7 billion in intangible assets as of December 31, 2025. Annual impairment testing required; company acknowledges risks of significant impairment charges if operating performance declines or competing technologies emerge.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'Future material impairments in the carrying value of our intangible assets, including goodwill, would negatively affect our operating results.'
  • Product liability litigation and potential recalls. Company acknowledges that product liability claims, safety alerts, and product recalls—regardless of merit or outcome—could have material adverse effect on business reputation and ability to attract and retain customers.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'Pending and future product liability claims and litigation could adversely impact our financial condition and results of operations and impair our reputation.'
  • Intellectual property litigation and claims. Company acknowledges ongoing patent infringement litigation with uncertain outcomes that could result in significant monetary damages, royalty payments, or loss of ability to sell current or future products.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'We are substantially dependent on patent and other proprietary rights, and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in the payment of significant monetary damages and/or royalty payments...'
  • Healthcare fraud and abuse compliance risks. Company subject to False Claims Act, Anti-Kickback Statute, Stark Law, Sunshine Act, FCPA, and UK Bribery Act; violations could result in criminal sanctions, civil penalties, fines, imprisonment, and exclusion from Medicare/Medicaid.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'If we fail to comply with healthcare fraud and abuse laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.'
  • Data privacy and cybersecurity compliance complexity. Company subject to FDA guidance on data security, multiple U.S. state privacy laws, and international privacy regulations (e.g., GDPR). Acknowledges evolving regulatory landscape and potential for substantial compliance costs and data breach penalties.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'If we fail to comply with data privacy and security laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.'
  • Cybersecurity and AI risks. Company acknowledges increasing sophistication and frequency of cyber attacks (phishing, ransomware, state-sponsored attacks). Use of artificial intelligence and machine learning in products and infrastructure exposes company to risks of inaccuracies, errors, interruptions affecting patient safety, and evolving regulatory uncertainty.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'We and our business partners are dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems and data, including from cybersecurity events, our business could be adversely affected.'
  • Regulatory and compliance enforcement risks. Company subject to rigorous FDA regulation and EU MDR; warnings letters, consent decrees, and enforcement actions could restrict manufacturing and marketing of products. Regulatory approval delays for new products could adversely affect revenue realization.
    Source: ZBH_10k.txt — Item 1A Risk Factors, 'We are subject to complex and expensive laws and governmental regulations relating to the development, design, product standards, packaging, advertising, promotion, post-market surveillance, manufacturing, labeling and marketing of our products...'

Disclosed initiatives

  • Independent Board Oversight and Lead Independent Director
    Michael J. Farrell serves as Lead Independent Director (appointed May 2025). Board consists of 9 independent directors plus CEO. Independent directors meet regularly without management. Lead Independent Director has explicit role and responsibilities equivalent to independent chairman. Board conducts annual self-evaluations and director evaluations.
    Ensures independent oversight of CEO and management; facilitates executive accountability and strategic risk management.
  • Compensation Recovery (Clawback) Policy
    Policy covers incentive-based compensation and includes clawback triggers for: (1) accounting restatement due to material noncompliance with financial reporting requirements under securities laws (applies to cash bonuses and performance-based equity); (2) certain violations of Code of Business Conduct and Ethics or conduct deemed detrimental to company interests (applies to equity-based incentives).
    Aligns executive incentives with financial integrity and ethical conduct; mitigates compensation-related fraud risk.
  • Stock Ownership and Retention Guidelines
    Rigorous stock ownership guidelines for directors and executives. New stock retention guidelines for named executive officers require shares received upon equity award vesting to be retained in accordance with ownership guidelines. Directors and executives prohibited from hedging and pledging company securities under insider trading policy.
    Aligns executive and director interests with long-term shareholder value; reduces speculative trading and related governance risks.
  • Annual Director Elections and Majority Voting
    All 10 directors elected annually by majority of votes cast. Majority voting and director resignation policy in uncontested director elections. Proxy access right permits shareholders to include director nominees in proxy materials.
    Enhances director accountability and shareholder voice in board composition.
  • Board and Executive Succession Planning
    Board conducts robust succession planning for senior management, key employees, and third parties (distributors, sales agents). Compensation and Management Development Committee oversees human-capital risk management alongside Board.
    Reduces key-person and organizational continuity risks; supports enterprise resilience.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Zimmer Biomet Holdings, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Zimmer Biomet Holdings, Inc. in the app for interactive charts and portfolio building.

Open Zimmer Biomet Holdings, Inc. in Missionomics

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)

Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics